Targeted deep sequencing of CD341 cells from peripheral blood can reproduce bone marrow molecular profile in myelodysplastic syndromes This study includes 48 patients which were analyzed by TDS using either a hybridization probe-based (Supporting Information Table S1) or an amplicon-based TDS sequencing panel (Supporting Information   Table S2 ). We analyzed bone marrow cells (BMC), PB mononuclear cells (PB-MC), and immunomagnetically enriched CD34
1 PB cells (PB-CD34) (Supporting Information Figure S1 ).
To identify molecular markers of clinical relevance, we screened genes previously reported to be frequently mutated in MDS and other myeloid malignancies. Tables S3 and S4) .
Overall, the combined application of classical cytogenetics, molecular karyotyping, and TDS identified genetic alterations in 43/48 (90%) patients.
TDS allowed the identification of 105 mutations in 24 genes. The highest mutation frequencies were observed for TET2 (n 5 13, 27%), SF3B1 (n 5 10, 21%), SRSF2 (n 5 10, 21%), ASXL1 (n 5 7, 16%), EZH2
(n 5 6, 13%), ZRSR2 (n 5 6, 13%), RUNX1 (n 5 5, 10%), U2AF1 (n 5 5, 10%), and TP53 (n 5 4, 8%) (Supporting Information Figure S2 ).
As previously reported we detected an increased number of genetic lesions in high-risk WHO subtypes (Supporting Information Figure S3A) and found a correlation between the average number of genetic aberrations and the IPSS-R prognostic risk score (Supporting Information Figure Comparison of the TDS results from BM and PB revealed that TDS allows detection of somatic mutations also in PB samples ( Figure   1A ). For non-enriched PB, this was previously shown, 4 while in the current study we have added PB-CD34. We were able to detect 93/105 mutations (89%) in all sample types (BMC, PB-CD34, and PB-MC) (Supporting Information Table S5 ). In BMC, we found 100/105 (95%), in Mohamedali et al. 4 However, the differences were not statistically significant. The significant deviation that we observed potentially resulted from a more stringent removal of SNPs in our dataset due to the analysis of the germline sample (CD3 A similar experimental setup was previously used by Braulke et al. 5 The authors applied FISH analysis on CD34 1 cells from PB and BM and observed a slight but not significant difference. It is likely that we did not observe such differences due to the analysis of unselected BMC.
It is noteworthy that we also observed apparent variations of the VAF values in PB-MC compared to BMC or PB-CD34 for some mutations. However, in most cases only individual mutations of the patient were affected and in just two cases the differences would have resulted in a changed assessment of the clonal hierarchy that was estimated by the VAF (Supporting Information Table S5 ). 
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